United States (National)
Not enough data
Allison Gatlin's coverage primarily focuses on the healthcare and pharmaceutical industry, with an emphasis on investment analysis and data citations. To effectively reach out to her, consider providing insights related to new drug developments, company financials, or market trends within the healthcare and pharmaceutical sector.
Given Allison's focus on investment analysis and data-driven reporting, she may be receptive to pitches that include statistical evidence or exclusive access to pertinent industry data that supports a particular trend or development in the healthcare and pharmaceutical field.
While Allison does not have a specific geographic focus mentioned, her coverage indicates a global view of the healthcare and pharmaceutical industry. Therefore, pitches should encompass international as well as domestic perspectives when relevant.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Allison Gatlin
IBD Composite Rating Industry Group Ranking Emerging Pattern Consolidation A sideways pattern that doesn't fit traditional base definitions.
By: Allison Gatlin
Guardant Health GH ) stock tumbled Monday after losing a patent battle against privately-held TwinStrand Biosciences and the University of Washington.
By: Allison Gatlin
Jazz stock bounced off its buy zone Tuesday after the Food and Drug Administration approved its drug, Ziihera, to treat a form of stomach cancer.
By: Allison Gatlin
Boston Scientific BSX ) stock crumbled Wednesday after the company said a cybersecurity incident interrupted its ability to process and ship customer orders.
Spyre Therapeutics SYRE ) took a hit Wednesday after its experimental rheumatoid arthritis treatment failed to pass muster in midstage testing.
Revolution Medicines RVMD ) won Food and Drug Administration approval Wednesday for the pancreatic cancer treatment that once caused its stock to skyrocket more than 40% in a day.
By: Allison Gatlin
Amgen (AMGN) and AstraZeneca's (AZN) asthma drug, Tezspire, scored Thursday in an esophageal disease that affects an estimated 470,000 patients in the U.S.
By: Allison Gatlin
Guardant Health stock tumbled Monday after losing a patent battle against privately held TwinStrand Biosciences.
By: Allison Gatlin
Cytokinetics CYTK ) scored the first-ever win for a Phase 3 study in non-obstructive hypertrophic cardiomyopathy on Friday, putting it on a path to overtake Bristol Myers Squibb BMY
By: Allison Gatlin
Cytokinetics scored the first-ever win for a Phase 3 study in non-obstructive hypertrophic cardiomyopathy on Friday.
